ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Nykode Therapeutics (NYKD.OL)
Nykode Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Oslo Børs · Norway
NOK 3.13▲ 0.00%
Prices as of Oct 27, 2026 · NOK
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Nykode Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Nykode Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Nykode Therapeutics a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between NOK 2.53 and NOK 3.59; in 9 out of 10, between NOK 1.86 and NOK 4.89. Estimated annual volatility is 110%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- NOK 1.2B
- Market cap (USD)
- $129M
- 52-week high
- NOK 5.20
- 52-week low
- NOK 2.06
- Revenue (12 months)
- $0.5M
- Net margin
- 0.0%
- Beta
- 0.86
What this means
ATLAS does not publish a fair value for NYKD.OL right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks NYKD.OL has traded between NOK 2.06 and NOK 5.20. Today it is 39.8% below that high and 52% above its low.
Its beta is 0.86: it moves roughly in line with the market.
About the company
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases.
Want to see everything about Nykode Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Nykode Therapeutics do?
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases.
What is the chance NYKD.OL goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, NYKD.OL ends the month between NOK 2.53 and NOK 3.59.
How big is Nykode Therapeutics and what is its P/E ratio?
Nykode Therapeutics's market capitalization is NOK 1.2B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is NYKD.OL?
ATLAS estimates annual volatility at 110%. In a typical month, half of the outcomes end between NOK 2.53 and NOK 3.59.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer